Replies to post #140057 on Biotech Values

[mcbio]

Good luck with that -g-. (One of the characteristics of ONTY is that they do not do the optimal set of raises.)

Yeah, I think you're right on that. ; ) I think you are similarly skeptical of Stimuvax's chances for P3 success, but do you think ONT-10 is a promising candidate? It sounds promising to me on the surface, but there is obviously no hard clinical data yet.

[BTH]

Whatever Bob Kirkman decides to do, rest assured, it will be detrimental to shareholders.

I wonder if Kirkman has figured out what a p-value is (not relating to his own trial, but ANY trial).